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1.1-Relevance of Preeclampsia (PE) 
 
PE is a pregnancy-related condition, classically defined as high maternal blood 
pressure associated with protein in urine. The prevalence and the impact of PE 
vary according to the economic resources of the country: the lower the economic 
status of the country, the higher the prevalence and the impact in maternal and 
neonatal health. It affects about 2-3% of pregnancies in developed countries and 
up to 7 times higher in developing countries, and it is a major contributor to 
maternal and neonatal mortality. Preserving maternal health has become in the 
21st century the main goal of maternal public health institutions in order to 
struggle against poverty and inequality. 99% of maternal deaths occur in low- and 
middle –income countries and PE and eclampsia is responsible for up to 10-15% of 
these.  Consequently, many efforts have been made to improve the prediction and 
management of PE.  
Globally, PE outcomes are often satisfactory, but it can be devastating and life 
threatening for both the mother and the foetus.  
 
PE is classified as the third cause of global maternal deaths, with an estimated 
100,000 deaths/year worldwide (1).  In developed countries, PE is the primary 
cause of maternal admission to the intensive care unit (2) and the second cause of 
maternal death(3), after maternal haemorrhage. Maternal morbidity can be 
significant in impact, especially in cases of severe PE, in terms of renal insufficiency 
at one year follow-up, cerebral infarction, cardiac arrest or liver failure(4). PE is 
also associated with a higher rate of caesarean birth(5) and it has been postulated 
as a cause for postpartum depression associated with the unexpected experience 
of facing an admission to the intensive care unit or a very premature deliver(6). A 
contribution of PE to maternal cardiovascular disease in the long term has also 
been described(7) for a priori healthy patients, in terms of later ischemic heart 
failure, diabetes or impaired glucose tolerance.  
 
PE is also associated with increased perinatal morbidity and mortality, being 
responsible for 10% of the six million perinatal deaths (8) and 15% of the eight 
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million of premature deliveries worldwide (9). It also accounts for a substantial 
proportion of the 20 million low birth-weight infants in developing nations. These 
impacts are more prevalent when access to neonatal intensive care is limited: the 
infant mortality rate is 3 times higher in low-and middle-income countries than in 
high-income countries(10). Complications associated with premature delivery 
include respiratory distress, apnea, jaundice, kernicterus, feeding difficulties, 
hypoglicemia, seizures and periventricular leucomalacia, all of which usually 
prolong hospitalization (11). 
 
For all these conditions, an accurate identification of those patients at highest risk 
of complications remains a goal for modern obstetrics in developed countries. This 
would lead to a more appropriate management of these high-risk patients with a 
more intensive strategy and the possibility of home monitoring for those patients 
with a low-risk of complications.  
 
 
1.2-Physiopathology of PE 
PE is a maternal endothelial disease, which exclusively appears during pregnancy 
and disappears with the extraction of the placenta, and currently, its 
physiopathology is not fully understood. It is known that a remodelling of spiral 
uterine arteries and formation of placental villi play a key role in the normal 
placental development, the vital structure that will guarantee maternal-foetal 
exchange functions and blood supply. This remodelling is believed to occur prior to 
the trophoblastic invasion and may be mediated by renin-angiotensin system and 
by maternal hormonal factors. There seems to be an associated secretion from the 
extravillous trophoblast of a wide variety of hormones and growth factors directly 
into the maternal blood. These factors, including angiogenic factors as Placental 
Growth Factor (PlGF) and Vascular Endothelial Growth Factor (VEGF), are 
suspected of being implied in the angiogenesis and vascular remodelling 
independently to the trophoblastic invasion of the vessel walls(12). 
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In normal pregnancy, arterial remodelling commences in the first weeks of 
gestation when the extravillous trophoblast cells from the placenta invade the 
uterus (Figure 1). The arterial vessel wall loses smooth muscle cells and elastic 
tissue, resulting in an expansion of the mouth of the arteries as they drain into the 
intervillous space within the placenta(13). Remodelled arteries will lose their 
capacity of constriction, ensuring the blood supply to the placenta. In addition, the 
velocity and pressure of the inflowing blood is significantly reduced, minimizing 
hemodynamic damage to the delicate placental villi. 
 
 
 
 
 
                        
                        
                        
 
 
 
Figure 1. Physiological trophoblastic invasion (by Fàtima Crispi and Col.) 
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Nevertheless, when these vascular transformations are incomplete and the 
transfer of substances between the foetal-maternal units is hindered, placental 
dysfunction emerges leading to endothelial dysfunction, the baseline of a maternal 
systemic syndrome called PE (Figure 2).  
In the first phase, impaired invasion of trophoblast results in narrower spiral 
arteries with an increased capacity of constriction. In a second phase, the increase 
in the velocity of blood entry causes hemodynamic damage and oxidative stress in 
the intervillous space. Parallel, intermittent repetitive placental underperfusion 
due to the excessive constriction of the vessel walls, a condition easily studied 
through Uterine Artery Doppler (14), is said to be the main cause for placental 
oxidative stress. This condition leads to an ischemia/reperfusion type injury of the 
placenta (15) and an increased secretion of pro-inflammatory cytokines and 
angiogenic regulators by the abnormal placenta (16), triggering in consequence a 
maternal endothelial dysfunction(17). An imbalance between the anti-angiogenic 
Figure 2. Impaired Trophoblastic invasion and Complications 
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factors like soluble endoglin (sEng) and the soluble vascular endothelial growth 
receptor (sFlt-1) and pro-angiogenic factors like placental growth factor (PlGF) 
and vascular endothelial growth factor (VEGF) may result in generalized 
endothelial dysfunction (18) leading to hypertensive syndrome and 
microangiopathy (19-21) in a third and last phase of the disease. Whether this 
imbalance of anti-angiogenic factors is due to excess of anti-angiogenic molecules 
or by a reduction in pro-angiogenesis molecules bio-synthesis, is today a matter of 
debate. 
The systemic endothelial disease will sub-clinically impair, through a systemic 
maternal inflammatory response, certain physiological pathways: the vascular 
reactivity to modulation of vascular substances, the activation of the coagulation 
cascade and the increase of capillary permeability (22). Cytokines will inhibit 
vascular systemic relaxation and will increase the production of factors like 
Tromboxane, leading to an imbalance among the Tromboxane/Prostacicline ratio 
and producing the contraction of smooth muscle cells. 
The end spectrum of this endothelial cascade will trigger the maternal clinical 
disease, with maternal hypertension and renal permeability impairment with 
proteinuria. Other maternal organ dysfunction as hepatic disease, neurological 
manifestations or haematological complications can also be present.  
 
1.3-Definition and classification 
Classical definition of PE according to the International Society Study of 
Hypertension in Pregnancy (ISSHP) was, up to this year, maternal hypertension 
defined as a resting blood pressure of ≥ 140/90 mmHg on two occasions at least 4 
hours apart, and the presence of proteinuria defined as ≥0.3 g/24 hours or a 2+ 
urine dipstick, beyond 20 weeks of pregnancy in a previous normotensive woman. 
ISSHP has recently published an updated definition of PE based on the deeper 
knowledge about the physiopathology of the disease and the emerging concept 
that PE may indeed have several subtypes(23). This revised concept defined PE as 
maternal hypertension after the 20 weeks of gestation and the coexistence of one 
of the following new onset conditions: 
• Proteinuria 
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• Maternal organ dysfunction: renal insufficiency, liver involvement, and 
neurological or haematological complications  
• Utero-placental dysfunction: intrauterine growth restriction 
 
How to define PE is of utmost importance. Nevertheless another essential concept 
is the gestational age at the clinical onset of the disease. Some studies have shown 
that gestational age at diagnosis of PE is associated with different biochemical and 
clinical features (17, 24) and it is one of the most important parameters in terms of 
prognosis. Early PE is defined as onset of PE before 34 weeks of gestation and Late 
PE defined as onset above 37 week. This gestational-age classification would seem 
more accurate than the classical one, based in the severity of clinical 
manifestations, and it would better reflect the scope of the disease. Nevertheless, 
both classifications are appropiated in approximately 80% of early PE cases, 
where the disease is manifested in a more severe way. 
 
Although the pathophysiology of PE is not yet fully understood, evidence supports 
the concept that Early and Late PE would be two different entities (25, 26). 
Certainly, this distinction is not merely an academic issue; it has profound 
consequences for clinical practice, as disease onset before 32 weeks gestation is 
associated with a 20-fold increased risk of maternal mortality(22). Similarly, the 
likelihood of perinatal mortality or severe neonatal morbidity is 16 times higher in 
early-onset PE(27).  
 
1.3.1-Early PE 
An impairment of spiral arteries remodelling and an imbalance in angiogenic 
factors are believed to be the basis of Early PE. It is almost invariably associated 
with placental insufficiency because of defective trophoblastic invasion. Abnormal 
uterine artery Doppler is usually present (26). Early PE can have serious 
consequences for the mother and the baby and it is often associated with greater 
risk of foetal growth restriction (28) and higher maternal and perinatal morbidity 
and mortality (29, 30). Expectant management has demonstrated to improve 
neonatal outcome in selected cases and to decrease neonatal care intensive unit 
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admittance and neonatal respiratory distress (31, 32). In consequence, decision-
making basically consists of a trade-off between reducing the risks of prematurity 
by prolonging gestation and minimizing the risks of maternal complications by 
delivery. 
 
1.3.2-Late PE 
Late PE form is fourfold more prevalent and in general, placental involvement is 
minimally present and in consequence low incidence of uterine artery Doppler 
impairment is observed. A pre-existing maternal systemic inflammation in a 
patient with maternal constitutional parameters – principally High Body Mass 
Index or maternal predisposing diseases for example cardiovascular disease or 
metabolic syndrome – would trigger a systemic cascade and oxidative stress in the 
context of a normal placenta. Although the maternal and foetal prognosis is much 
better, it is still associated with some maternal and foetal morbidity (27). 
 
1.3.3-Severe PE 
Severe PE is defined according to the ISSHP by the presence of the following 
criteria: blood pressure ≥ 160/110 mmHg in 2 or more determinations, 
proteinuria ≥5 g/24 hours, or the presence of maternal complications that 
included (1) eclampsia and other neurologic manifestations (visual disturbances 
or severe headache that persisted more than 24 hours), (2) HELLP syndrome 
(lactate dehydrogenase >600 IU/L, aspartate transaminase >62 IU/L, platelet 
count <100,000 /L), (3) acute renal failure defined as creatinine above 1,2g/dL, (4) 
subcapsular hepatic hematoma, (5) pulmonary oedema and (6) the presence of 
disseminated intravascular disease. 
Nevertheless, evidence suggests that stratifying women, especially with early onset 
PE, as high and low risk for adverse events cannot confidently rely upon the classic 
severity criteria, which are based on non-specific clinical and laboratory 
markers(33-36).  
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1.4-Management of early and severe PE 
Neonatal morbidity and mortality is inversely related with gestational age at 
delivery. Delivering below 28 weeks, especially in those IUGR foetuses usually 
associated with early PE, involves a mortality rate of at least 50% with a high risk 
of morbidity (37, 38). On the other hand, it is well known that the prognosis of 
neonates delivered above 34 weeks gestation in a tertiary care centre is excellent 
with a survival rate of almost 100%. Several studies have demonstrated that 
expectant management of early and severe cases could reduce neonatal morbidity 
with a low risk for the mother.  Preterm delivery is associated with respiratory 
distress, necrotizing enterocolitis and intraventricular haemorrhage. Nevertheless, 
continuing with the pregnancy could worsen maternal clinical state and would 
expose the foetus to a hostile environment due to the unstable haemodynamics 
and the consequent risk of placental abruption and intrauterine death. Therefore, 
the election of when to deliver should be based on objectives and reliable 
parameters. Recent publications have defended an expectant management for 
early and severe cases, advocating a reduction of neonatal morbidity without 
increasing maternal morbidity and mortality(39). 
 
1.5- Complications of preeclampsia and implications for management  
PE can potentially result in a devastating disease for the mother and the foetus, 
forcing intensive care management in those cases at higher risk of complications. 
Although an appropriate treatment can avoid most of the severe complications, some 
patients will present them in any case and an appropriate identification of them is of 
utmost importance. The most prevalent ones are reviewed as follows 
1- Eclampsia: It has the highest mortality rate at 1.8%. It is produced because of 
a vasospasm of cerebral arteries that leads to ischemia and endothelial 
disease. Its incidence has decreased because of the improvement in the 
management of these patients and the implementation of preventive 
treatment with magnesium sulphate. It occurs in 2-3% of severe PE and in 
0.6% of mild PE and it presents more frequently before delivery.  Persevering 
headache is present in 70% of the cases. It is important to highlight that 
almost 4 out of 10 patients with eclampsia neither have hypertension nor 
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proteinuria when convulsions happen. The presence of eclampsia will force to 
end up the gestation once the patient and the foetus will be hemodynamically 
stable. 
2- HELLP syndrome: Its clinical presentation depends on the spread of 
endothelial disease and the deposits of fibrin. It affects 4-12% of those 
patients with severe PE and it is more frequent prior to the delivery. It is 
identified when haemolysis, elevation of liver enzymes and thrombocytopenia 
coexist, but in some cases, some of these criteria can be absent. Anaemia will 
be due to a mycroangiopathic Haemolysis and schistocytes can be observed.  
Liver disease will be secondary to the presence of fibrin in the hepatic 
sinusoids. The end spectrum of this affection will be subcapsular haematoma 
and liver rupture, resulting in a high-risk situation for the mother. 
Thrombocytopenia is produced because of platelets destruction and an 
increased adherence of those to the endothelial vessels. Its presence will be 
related with a higher incidence of disseminated intravascular coagulopathy 
(DIC) and placental abruption. There is still controversy whether we should 
terminate the pregnancy once HELLP syndrome is diagnosed.  
3- Pulmonary acute oedema: its prevalence is 2-6% among those patients with 
severe PE and its origin is multifactorial: decrease in the oncotic pressure 
because of hemodilution, increase in the vessels permeability and cardiac 
ventricular dysfunction. This scenario could be impaired with the 
administration of glucocorticoids for the acceleration of foetal lung 
maturation. Its presence is frequently associated with other vital organs 
affections, so that termination of pregnancy will be of vital importance once 
the patient is stable. 
4- Acute renal failure: It affects 1-8% of severe PE and it is frequently related 
with the presence of haemorrhage or DIC and its presence will lead to the 
pregnancy being terminated. 
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1.6- Prognostic challenges in PE 
When a PE is suspected, some aspects must be taken into consideration. After 
initial assessment and stabilization of the patient based on blood pressure control 
and prevention of eclampsia if necessary, time of delivery is called into question. 
For this reason, knowing how the mother and the baby is essential: a check must 
be made as to whether there is any evidence of a maternal end-organ complication 
or whether the foetus is growth-restricted and shows signs of foetal compromise. 
Even though delivery is the only definitive treatment, the goal of clinical 
management in developed countries, especially in early PE, is to manage the 
pregnancy expectantly (40), extending gestational age for enough time to decrease 
the risks of prematurity for the foetus or at least, to provide time for 
administration of corticosteroids for foetal maturation of lung, digestive system 
and brain. In developing countries with scarce resources, the identification of 
patients at highest risk of adverse outcomes could allow the transfer of these 
patients to a well-equipped hospital for their proper management. 
Therefore it is of utmost importance to improve the stratification of women at risk 
of adverse maternal and foetal outcome. This would allow the establishment of 
subgroups of patients for surveillance either as outpatients or as inpatients with 
the possibility of immediate delivery(41, 42).  
 
Current prognostic assessment is based on classical parameters defined by the 
ISSHP. Severity of maternal hypertension, presence of proteinuria, clinical 
evaluation and laboratory blood testing would detect maternal organ damage. 
Nevertheless, several authors have recently defended the concept that maternal 
symptoms or severe proteinuria should be used cautiously when taking clinical 
decision as these prognostic tools may have some limitations(35).   
 
Low predictive values of blood pressure for severe adverse maternal and perinatal 
outcomes would limit its clinical utility(43, 44). Blood pressure can be affected by 
a variety of factors. Menzies (42) concluded that almost all the criteria defining a 
severe PE either in the Canadian or the American guideline do not predict adverse 
maternal nor perinatal outcome, and in consequence its utility, especially in those 
pregnancies far from term, should be taken with caution. In this studied cohort 
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among 737 pregnancies, dyspnoea, low platelets below 100x109/L, elevated liver 
enzymes or creatinine and HELLP syndrome were associated with maternal 
adverse outcome. Only diastolic blood pressure above 110 mmHg and suspicion of 
placenta abruption were associated with adverse perinatal outcome.  
Proteinuria is a non-specific clinical sign, it is affected by the method of 
measurement and it is a poor predictor of adverse pregnancy outcome(45). The 
Pre-eclampsia Integrated Estimate of Risk (PIERS) study (35), a multicentre 
prospective cohort study carried on in 2011 among 2023 pregnant women with 
the diagnosis of PE, HELLP syndrome or superimposed PE whatever gestational 
age was, was designed to investigate the maternal risks associated with PE. Its 
main goal was to create a continuous quality improvement project for women 
hospitalized with preeclampsia. For that purpose, they collected all the candidate 
predictive variables, considered as those available, measurable and reliable ones 
within the first 48 hours after the hospitalization. In this study, proteinuria was 
not an independent valid predictor of maternal adverse outcome. Indeed, the 
range to consider severe proteinuria has been modified along the years and 
nowadays, some guidelines question whether it should be included in the severity 
criteria list. 
 
Moreover, some of the criteria for severity as HELLP syndrome, although 
presenting an acceptable association with adverse maternal outcome, have limited 
capacity of prediction for foetal adverse outcome (46). 
The PIERS study has proposed a multi parametric approach of maternal symptoms 
to assess more accurately maternal outcome. No symptom alone achieved an area 
under the ROC curve value above 0.7. The integrated model reached an area under 
the ROC curve of 0.88 to predict adverse maternal outcome in the first 48 hours 
after hospitalization and above 0.70 in the period between the second and the 
seventh day after the inclusion with 13% of false positive rate. In those early PE 
cases, the area under the curve reached 0.85. This algorithm incorporated 
gestational age at diagnosis, thoracic pain, creatinine levels, platelets 
concentration and aminotransferase aspartate and oxygen saturation (36). 
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When assessing for foetal prognosis, clinical maternal parameters perform even 
worse. The presence of IUGR has been proposed several times as a criteria for 
severity at onset of PE. Nevertheless, the ISSHP current classification of severity 
does not contemplate it. Although almost 75% of early PE present with IUGR, 
foetal growth restriction is much less present in late PE. In that sense, Doppler 
study has emerged as a useful tool in the evaluation of high-risk patients and there 
is strong evidence that abnormal individual vessel indices correlate with 
pregnancy outcomes (47, 48). Specifically, umbilical artery Doppler has 
demonstrated significant diagnostic efficacy in identifying foetal compromise in 
pregnancies complicated with PE (49-51), especially when integrated with other 
current foetal monitoring tests. Scarce data exists about the most frequently 
altered ultrasound parameters in the pathology (52) and even fewer, relating 
Doppler findings with foetal prognosis. Umbilical artery would have limited 
capacity in absence of IUGR. 
 
The limitations in the prediction capacity of these prognostic tools could lead to an 
increased and often unnecessary intervention in many women. On the other hand, 
their non-specificity could lead to missed or delayed diagnosis of life-threating 
disease, resulting in a progression to severe PE or eclampsia. 
 
Consequently, establishing new markers of severity has been identified as a major 
challenge for PE research in the upcoming years. In that sense, some of the 
parameters used in the prediction of the disease either at 1st or 2nd trimester have 
emerged as candidates to better classify those preeclamptic patients and to ensure 
an appropriate level of clinical surveillance. An evaluation about the placental 
dysfunction itself, throughout Uterine Artery Doppler or angiogenic biomarkers, 
has been proposed as a novel approach to the prognosis evaluation of PE. 
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1.6.1-Uterine Doppler  
 
 
Third-trimester abnormal uterine artery Doppler has been related to worse 
perinatal outcomes among patients both with and without pregnancy 
complications(53). Furthermore, in PE clinical severity has been directly related to 
the extension of placental ischemia: the larger the ischemia, the more severe the 
clinical manifestations and the poorer the perinatal outcomes (54). Accordingly, 
the study of the uterus-placenta unit would seem an interesting parameter for the 
prognostic assessment of the disease. Few studies have evaluated uterine artery 
Doppler as a prognostic tool at the onset of PE.  
 
Frusca et al. (55) evaluated uterine Doppler for the prediction of pregnancy 
outcome in the different Gestational Hypertension entities. Those preeclamptic 
patients with impaired Doppler presented poorer outcomes than those with 
normal Doppler evaluation. Furthermore, those patients with gestational 
hypertension, usually known as a milder affection, who also had abnormal uterine 
Doppler at diagnosis, presented pregnancy outcomes similar to those preeclamptic 
patients. Li H. and others (56, 57) concluded that abnormal Doppler is much more 
frequent at earlier the gestational age of onset of the disease. In that sense, the 
frequency of abnormal uterine artery blood flow was 87% in pregnancies 
delivered before 34 weeks, 71% in those delivered at 34-37 weeks and only 28% 
in term pregnancies. 
 
Later, Ghi et al. (58) evaluated the utility of Uterine Doppler at hospital admission 
in those preeclamptic patients diagnosed above 34 weeks. Women with late-onset 
PE showed a higher risk of perinatal complications when abnormal uterine 
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Doppler was present. Nevertheless, this finding was not related to adverse 
maternal outcomes. These observations supported the idea that severe PE near 
term may coexist with low resistance placental circulation and may hence be 
promoted by factors others than those commonly advocated at earlier stage. 
Valensise et al (59) reported that patients who were diagnosed with Early PE had 
higher total vascular resistance and lower cardiac output, while late-onset patients 
had higher pre-pregnancy BMI, higher cardiac output and lower total vascular 
resistance. 
 
However, the role of uterine artery Doppler evaluation in the identification of 
pregnancy at risk of maternal or foetal morbidity with early-onset PE has not been 
investigated. In that context, our first article evaluated the performance of Uterine 
Doppler in the prognostic assessment of adverse outcomes. Our second article 
further explored the performance of Uterine Doppler in early-PE.  
 
1.6.2- Angiogenic factors 
As we have described in the pathophysiology, the excess in anti-angiogenic factors 
produced by the placenta may cause damage to the vasculature and distal organs 
(60, 61). Karumanchi et al. (62) showed that excess sFlt-1 would mediate the 
multiple symptoms of PE. Parallel, circulating PlGF levels are much lower in those 
patients who would develop PE than in normal pregnancies(63). The 
concentration of circulating PlGF begins to decrease 9 to 11 weeks before the onset 
of pre-eclampsia, with substantial reductions during the 5 weeks before the onset 
of hypertension or proteinuria. 
 
In that context, placental growth factor (PlGF) has emerged as a potential tool to be 
included in diagnostic and prognostic algorithms(64). Mainly produced in the 
placenta, PlGF induces vasodilatation of uterine arteries, and would therefore 
contribute to uterine vascular remodelling during pregnancy. This pro-angiogenic 
marker seems to be a more sensitive and precise predictor of PE than any other 
single biomarker, as it reflects placental function(65). Low concentrations of PlGF 
may reflect poor placentation and thus a response to oxidative stress in the 
placenta, which are mainly present in early PE(66, 67).  
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The Early-PE has been correlated with a more frequent presence of lesions 
consistent with utero-placental perfusion and with a lower PlGF (68). In a well-
designed prospective study, Chappell et al. evaluated the diagnostic accuracy of 
Triage PlGF in those women presenting 20.0 to 40.6 weeks gestation with 
suspected PE for predicting PE requiring delivery within 14 days. The test 
performance had a sensitivity of 95% (86-98%), a specificity of 56% (49-63%) and 
a negative predictive value of 97% (92-99%). The author concluded that in women 
presenting suspected PE under 35 weeks’ gestation, a low PlGF level would rule in 
women requiring preterm delivery and high PlGF would rule out preterm delivery 
within 14 days.(69) 
Different assay platforms for the evaluation of PlGF have been commercialised, 
most of them only measureable in plasma sample.  The Triage PlGF test (Alere, San 
Diego, USA) is a point-of-care fluorescence immunoassay that measures non-
complexed biologically active form of PlGF. It has been designed to be compatible 
with EDTA plasma and whole blood samples. Samples must be frozen to -80ºC. 
Test results are typically obtained within 15 minutes and can be displayed and 
printed at the point-of-care. Valid reference ranges for PlGF in normal pregnancies 
have been published (70).  The reportable range is 12-3000 pg/mL. Original cut-off 
levels based on the 5th centile of a PlGF level in normal healthy pregnant 
population would not differ significantly from an absolute threshold of 100 ng/ml 
in women presenting with signs and symptoms of PE before the 35th week of 
pregnancy (69). Therefore, the Pelican study supports that only two cut-offs (12 
and 100 pg/mL) would be required for interpretation of a PlGF measurement in 
preterm PE: 
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PlGF concentration Risk 
PlGF<12 pg/mL Highly abnormal and suggestive of severe placental 
dysfunction and likely to deliver within the next 2 weeks 
PlGF ≥12 pg/mL and 
<100 mg/mL 
Abnormal and suggestive of placental dysfunction with 
increased risk of preterm delivery 
PlGF≥100pg/mL Normal and suggestive of patients without placental 
dysfunction and unlikely to require delivery within the 
next two weeks 
 
Table 1. Risk of PE according to PlGF concentration 
 
Alere Triage PlGF test, compared to the other platforms as Delfia PlGF or 
Elecsys PlGF presented significantly lower PlGF values among cases (71).  In this 
study published by Benton, mean values for Triage PlGF and Elecsys PlGF in 
those cases with early PE were 12.0 and 62.5 pg/mL respectively (p<0.001) and 
14.7 and 90.0 pg/mL in those late PE-onset cases (p<0.001)  
   
Sibiude J. et al. (72) evaluated in a double-blind prospective study the predictive 
value of Triage for PE and adverse outcomes in patients with suspected PE or 
IUGR. Those preterm pregnancies below 34 weeks with PlGF level<12 pg/mL at 
admission experienced severe adverse outcomes in 96% of cases. 
 
Several studies have also been published evaluating other platforms of PlGF that 
combine pro and anti-angiogenic biomarkers. An elevated sFlt1/PlGF ratio 
increases the risk of adverse outcomes 47 times (73). The addition of sFlt1/PlGF 
ratio to classical clinical parameters, for example hypertension and proteinuria, 
may increase the prediction capacity of complications. 
 
However, this excellent profile of PlGF as a marker of early PE may limit its clinical 
applicability for prognostic assessment if a high number of women already have 
very low levels at the onset of PE. The median of PlGF was of 12 pg/mL in women 
with either early onset or preterm PE (71). 
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1.6.3-Combination of both parameters 
Another approach in the current literature combines Doppler and angiogenic 
parameters in the prediction of adverse outcomes in preeclamptic women. 
Molvarec et al. (74) in an observational retrospective study among 89 pregnant 
women with hypertensive disorders (12 HELLP syndrome, 19 PE and 17 with 
superimposed PE) compared the prediction capacity of foetal adverse outcomes 
for Triage PlGF and foetal Doppler evaluation at umbilical and foetal middle 
cerebral vessels. PlGF below 100pg/mL identified not only all women with 
hypertensive disorders who required urgent delivery following an abnormal foetal 
flow result but also those who had normal Doppler evaluation and needed to be 
delivered preterm due to pathological CTG or oligohydramnios. 
Gómez-Arriaga PL et al.(75)evaluated in a cohort study of early-PE the 
performance of Uterine Doppler in combination with sFlt-1/PlGF ratio to predict 
adverse maternal and perinatal outcomes. The addition of these parameters to GA 
at diagnosis did not improve the predictive capacity of maternal complications. 
Regarding the perinatal prognosis, the addition of these parameters, especially 
sFlt-1/PlGF ratio, to GA at diagnosis could improve the prognostic accuracy and 
could help inform a decision regarding whether to pursue expectant management. 
Moreover, the antiangiogenic-angiogenic ratio demonstrated a good correlation 
with the expected time to delivery. 
 
No information exists about what is the performance of these angiogenic 
parameters according to gestational age at diagnosis. In this context, the aim of the 
third article was to analyse the performance of PlGF for maternal adverse outcome 
according to the gestational age at onset.  
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2.1- Main hypotheses 
Preeclampsia has biochemical and biophysical features that could help to predict 
its complications and that could consequently modify its management in order to 
prevent them. 
 
 2.2-Specific hypotheses 
* In early onset PE, uterine artery evaluation at the onset of clinical disease could 
help in the identification of those patients at higher risk of maternal and neonatal 
complications. 
* In those cases with late PE, uterine artery evaluation at the onset of clinical 
disease could improve the identification of those patients at higher risk of adverse 
outcomes even better than classical Doppler fetal parameters as umbilical artery 
or middle cerebral artery.  
* In preeclamptic patients, maternal plasma concentrations of placental growth 
factors could have a limited capacity in identifying those at higher risk of adverse 
outcomes, especially in early-onset PE. 
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 3.1-Main objective 
To phenotypically characterize both early and late PE in terms of the uterine artery 
Doppler and angiogenic profile.    
 
3.2-Specific objectives  
* To evaluate the performance of uterine Doppler at onset of PE for the prediction 
of adverse pregnancy outcomes in early onset preeclampsia. 
* To evaluate the performance of uterine Doppler at onset of PE for the prediction 
of adverse pregnancy outcomes in late onset preeclampsia.  
* To evaluate the role of PlGF in the prognostic assessment of early PE according to 
the gestational age at onset. 
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STUDY 1 
Prognostic Role of Uterine Artery Doppler in Patients with 
Preeclampsia 
Meler E., Figueras F., Mula R., Crispi F., Bennassar M., Gómez O., 
Gratacós E. 
Fetal Diagn Ther 2010; 27: 8-13. 
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 Introduction 
 Preeclampsia (PE) affects about 2–3% of pregnancies 
and is a major contributor to maternal mortality with an 
estimated 50,000 deaths/year worldwide  [1] . PE is also as-
sociated with increased perinatal morbidity  [2] and mor-
tality  [3] .
 In recent years, it has been established that early- and 
late-onset PE are associated with different biochemical 
and clinical features  [4] : whereas the early-onset form is 
almost invariably associated with placental insufficiency 
and growth restriction, the late-onset form is more prev-
alent and, in general, placental involvement is minimally 
present. In patients with early-onset PE, expectant man-
agement improves neonatal outcome in selected cases, 
decreasing neonatal care intensive unit admittance and 
neonatal respiratory distress  [5, 6] . Also in selected cases, 
mild PE could be managed in an outpatient regimen un-
til term  [7] , providing a reassuring maternal and fetal as-
sessment. While the criteria of maternal risk on which the 
selection of cases for expectant management could be 
based are well defined  [7, 8] , fetal criteria are not as well 
established.
 Umbilical artery (UA) and middle cerebral artery 
(MCA) Dopplers are standard parameters in the manage-
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 Preeclampsia   Uterine artery Doppler   Perinatal outcome, 
adverse  
 Abstract 
 Objectives: To evaluate the predictive capacity of umbilical, 
cerebral and uterine artery Doppler in women admitted
for preeclampsia (PE).  Methods: 190 consecutive singleton 
pregnancies admitted with PE were included. Umbilical, ce-
rebral and uterine artery Dopplers were performed. The as-
sociation with adverse perinatal outcome was evaluated 
from 2  !  2 tables and multivariately by logistic regression. 
 Results: A total of 82 (43%) women had an abnormal uterine 
artery Doppler on admission, being more prevalent in ear-
ly-onset ( !  32 weeks) than in the late-onset PE (62 vs. 27%,
p  !  0.05). In both early- and late-onset forms, uterine artery 
Doppler showed a greater capacity than umbilical and mid-
dle cerebral artery Doppler for predicting adverse perinatal 
outcome.  Conclusion: Uterine artery Doppler was the best 
predictive parameter for perinatal outcome in pregnancies 
with PE and may be included as a primary surveillance test. 
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5.1-Results from the first study 
190 singleton pregnancies were included in this study and 85% (162/190) met the 
severity criteria. In 44% (84/190), the clinical onset of PE was before 32 weeks. 
Among the early-onset group, 96% of cases met severity criteria whereas 76% did 
in the late-onset group. Adverse perinatal outcomes were present in 1 out of 4 of 
all pregnancies (26.8%) and this prevalence tended to be higher in those early-
onset cases.  
 
When comparing the performance of uterine Doppler in predicting adverse 
perinatal outcome to umbilical artery or middle cerebral artery Doppler 
performance in patients with PE, the ROC curve analysis was 0.69 (95% CI 0.60-
0.78), 0.59 (95% CI 0.50-0.69) and 0.58 (95% CI 0.48-0.68) respectively and 
uterine Doppler resulted in the only parameter significantly associated with 
adverse outcomes. The best cut-off for uterine artery pulsatility index (PI) was the 
97.5th centile and the 95th centile for umbilical artery PI and middle cerebral artery 
PI. When evaluating the performance of those parameters according to the 
gestational age at the onset of the disease, those parameters performed much 
better in those early PE cases with a sensitivity of 79%, compared to 50% for late 
PE cases. Moreover, uterine artery PI remained the only parameter significantly 
related with adverse perinatal outcomes. 
 
When comparing in a regression analysis those Doppler parameters to standard 
clinical and biochemical parameters for the prediction of severity of the disease, 
the only parameter that significantly and independently predicted adverse 
perinatal outcomes was uterine artery Doppler, with an OR 4.17 (95% CI 1.97-
8.81; p<0.001). When stratifying for early- and late-onset clinical forms, the ORs 
were 3.34 (95% CI 1.05-10.6; p=0.04) and 5.18 (95% CI 1.63-16.47; p=0.005), 
respectively.  
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5.2-Results from the second study 
In this study, 120 singleton pregnancies were analysed. Uterine artery Doppler 
was abnormal in 53% (64/120) of the cases. 
Maternal and perinatal outcomes in the subgroup of severe early-onset PE were 
worse when the patients had an abnormal uterine Doppler at the onset of the 
disease. Gestational age at delivery was significantly lower in those patients with 
impaired Doppler (30.2 vs 32.7, p<0.001). The proportion of small-for-gestational 
age infants and abnormal umbilical artery Doppler was significantly higher in the 
abnormal uterine Doppler group. After adjustment by gestational age at delivery, 
those differences remained significant. Neonatal complications were significantly 
more common, especially in terms of 5-minute Apgar score <7 and perinatal death. 
Maternal complications in terms of HELLP syndrome, neurologic manifestations, 
acute renal failure and pulmonary oedema were also significantly more common 
(28% vs 5.4%, p=0.001) in those pregnancies with impaired Doppler. No cases of 
eclampsia, subcapsular hematoma or disseminated intravascular disease occurred. 
 
5.3-Results from the third study 
A total of 84 patients were included in the analysis. Eight (9.5%) patients had PE 
onset before 28 weeks, 37 (44.1%) between 28 and 31.6 weeks and 39 (46.4%) 
between 32 and 36.6 weeks. Earlier the onset of PE was, more frequent criteria of 
severity were present (linear p=0.002). In that sense, 87.5% of the patients with 
PE diagnosed below 28 weeks met severity criteria, 37.8% of those diagnosed at 
28 to 32 weeks and 23% of those diagnosed above 32 weeks. 
PlGF was undetectable in almost two-thirds of the patients, being much more 
frequent as earlier the onset of PE was. In consequence, PlGF was below 12 pg/mL 
in 87.5% of those PE diagnosed below 28 weeks, in 78.4% in those diagnosed 
between 28 and 32 weeks and in 41% of those above 32 weeks. (linear p=0.019). 
Only one out of 30 patients with severity criteria did not present with undetectable 
PlGF values. On the other way, 65.5% (35/58) of patients without complications, 
also had undetectable PlGF values. 
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6-DISCUSSION 
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According to the results of the first study, uterine artery Doppler at clinical onset 
of early-severe PE could identify those patients at higher risk of adverse maternal 
and perinatal outcomes. 
This hypothesis is similar to the one published by Ghi(58), who defended uterine 
Doppler at diagnosis to predict those patients at higher risk of neonatal 
complications in late-onset PE. In 2003 Frusca(55) also concluded that patients 
with gestational hypertension, the mildest affection of the gestational 
hypertension spectrum, with associated impaired uterine Doppler have similar 
outcomes to preeclamptic patients. 
Uterine Doppler examination is a validated surrogate of the trophoblastic invasion 
and placental perfusion. Most of our cases (78.1%) with impaired uterine Doppler 
had also abnormal umbilical artery. The association of abnormal umbilical Doppler 
with adverse neonatal outcomes has widely been demonstrated in high-risk 
patients(50).  
Although the association of impaired uterine Doppler with adverse maternal 
outcomes has not previously been described, abnormal uterine evaluation has 
strongly been related to findings in maternal circulating angiogenic factors 
compatible with endothelial dysfunction(24), the key parameter for the clinical 
maternal manifestations of PE. Evaluating angiogenic factors in our cases would 
have contributed interestingly to our results. 
Our study is the first study focusing on a well-identified early onset PE group, 
homogeneous and with similar risk factors among those patients with normal and 
abnormal uterine Doppler. 
The lower incidence of complications in our population and our acceptable but 
limited sample size resulted in some weak associations. This fact could constrain 
the extrapolation of our results into populations with poorer clinical outcomes.  
 
 
In the second study, in which all Doppler parameters were compared for their 
prediction capacity of adverse outcomes, uterine Doppler at admission resulted to 
be the best predictive parameter for perinatal outcomes in pregnancies with PE.   
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Umbilical artery Doppler has been described as the most predictive parameter 
associated with adverse outcomes in high-risk patients(50). The presence of 
abnormal umbilical flow is the first step in the cascade of deterioration of IUGR 
pregnancies. Nevertheless, it becomes abnormal only in advanced stages of 
placental dysfunction, as it requires an ischemia affecting more than 50% of the 
placenta to become clinically evident. Middle cerebral artery, which reflects 
regional brain perfusion, shows in a second term brain hypoxia, but it is also 
clinically relevant in advanced stages(76). In this scenario, uterine Doppler 
emerges as a candidate to better predict adverse outcomes in high-risk 
pregnancies. In the line of our results, Li (57) found that UtA artery pulsatility 
index was the best indicator of adverse outcomes, followed by umbilical artery 
pulsatility, in preeclamptic patients. It is notable that a in a recently reported 
longitudinal series (77), approximately one-third of abnormal third-trimester 
uterine Doppler studies occurred in women with normal scans during the second 
trimester, suggesting that a segment of placental disease emerges late in 
pregnancy. Hence, the potential advantage of a third-trimester uterine Doppler is 
the ability to detect placental insufficiency of differing pathways.  
 
Standard biochemical and clinical parameters have also been compared to uterine 
Doppler in the prediction of adverse perinatal outcomes in our second study. 
According to our results, abnormal uterine Doppler at the onset of PE was the only 
parameter that significantly and independently predicted adverse perinatal 
outcome. Doppler study may be even more predictive than blood pressure, 
maternal proteinuria or clinical prodromic neurological symptoms for the 
prediction of foetuses at higher risk. Zhang in the year 2001(44) already reported 
the limited capacity of blood pressure and proteinuria in the identification of 
perinatal risk but this study did not evaluate the results according to gestational 
age. More recently, the PIERS study(36) has concluded that maternal symptoms 
were poorly related to adverse perinatal outcomes. Alterations in biochemical 
parameters may reflect endothelial dysfunction in different organs of the maternal 
compartment may but may not be directly related the foetal compartment. 
Consequently, uterine Doppler could inform as to the affection of both 
compartments. In the case of impaired uterine Doppler, the risk of adverse 
 52 
outcomes for the mother and the foetus may be higher. A new definition of PE 
published this year by the ISSHP(78) has even excluded proteinuria as a sign of 
severity. It is therefore important to define parameters that could foresee better 
perinatal outcomes. According to our results, the role of normal uterine Doppler in 
early-PE is to rule out the occurrence of adverse outcomes, allowing a safe 
prolongation of pregnancy and in consequence foetal maturation. In late-PE, 
uterine Doppler identifies those pregnancies at higher risk that would benefit from 
a more intensive management of the pregnancy. 
 
The higher prevalence of severity criteria among our studied population could 
have increased the sensitivity and specificity but does not explain the differences 
between both groups. It would have also been interesting to know the prevalence 
of abnormal uterine Doppler at second trimester among our patients in order to 
evaluate whether those patients with persistent impaired Doppler would have 
worse outcomes than those with onset at third trimester. 
 
 
Finally in our third study, we challenged the suggested role of PlGF as a 
prognostic marker of disease severity. According to our results, 80% of the 
patients with PE onset before 32 weeks had very low PlGF plasma levels. Our 
findings add evidence to the current approach in the diagnosis of the disease. The 
finding of low concentrations of PlGF maternal plasma levels may help in the 
diagnosis of PE and could be useful in distinguishing PE from other hypertensive 
disorders, such as gestational hypertension and chronic hypertension. Knudsen 
(79) in a case-control study among preterm pregnancies demonstrated high 
sensitivity and specificity of low PlGF concentrations for the diagnosis of PE. 
According to our results, it is evident that the earlier the diagnosis is, the higher 
the proportion of these very low values is. Wikström (80) found that alterations in 
maternal plasma levels of angiogenic factors are more frequent and more 
pronounced in early-PE compared to late-onset PE: the median plasma 
concentration of PlGF was 21 and 5 times lower respectively. Nevertheless, our 
study is the first one to stratify the prevalence of low concentrations of PlGF in 
early-PE according to gestational age. 
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Furthermore, PlGF has also been proposed as a candidate to improve the 
prediction of both maternal and foetal adverse outcomes when the diagnosis has 
been firmly established. According to our results, PlGF values are very low before 
32 weeks’ gestation regardless of the presence of severity. These findings suggest 
that decreased PlGF is inherent in early-onset PE and therefore would add little 
prognostic value over the gestational age at onset. Chaiworapongsa (20) showed 
that in patients with early-PE, no significant differences in PlGF concentrations 
were found between mild and severe PE. Similarly, Sibiude (72) found that almost 
all patients (24 out of 25) with PE below 34 weeks and with severity criteria had 
PlGF concentrations below 12 pg/mL. 
Gómez-Arriaga (75) concluded that even if gestational age at onset was the best 
predictor of maternal and perinatal adverse outcomes, uterine Doppler in 
combination with angiogenic factors could slightly improve its performance. The 
combination of both parameters may reduce the high false positive rate. According 
to our two previous studies and to some other studies corroborating our results, 
uterine Doppler at diagnosis would identify women at higher risk of maternal 
complications. Moreover, some evidence has been published about the 
relationship between impaired uterine Doppler and angiogenic factors. It could be 
speculated that abnormal uterine Doppler is a marker of higher maternal 
endothelial dysfunction because of the adverse angiogenic profile. A recent study 
by our group has found that both uterine Doppler and maternal circulating 
angiogenic factor contribute in the prediction of placental underperfusion(81), 
which, in turn, is a placental pattern contributing to adverse perinatal 
outcomes(82).  
 
Some limitations of our study could be mentioned. PlGF can be measured by 
different assay platforms and the Alere Triage system has demonstrated lower 
values than other platforms.  This could explain the high proportion of very low 
values found in our study. The sFlt-1/PlGF has been proposed as a candidate even 
better that PlGF alone for the prediction of adverse outcomes in preeclamptic 
patients.  In our study, we did not measure sFlt-1 and this could allow better 
resolution than PlGF alone. Nevertheless, some series involving patients with 
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suspected PE demonstrated no benefit of the sFlt1/PlGF ratio over the PlGF alone 
to predict PE requiring delivery within 14 days. 
 
It is evident that a better identification of preeclamptic patients at higher risk of 
adverse outcomes is of utmost importance in order to manage more accurately the 
disease. Uterine Doppler could perform effectively as a predictor of adverse 
outcomes, in early and late PE. The role of angiogenic factor in the prediction of 
adverse outcomes needs to be more clearly defined, but it shows a potential in late 
preeclampsia. 
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7-CONCLUSIONS 
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1- Uterine Doppler was the best predictive parameter for perinatal outcomes 
in pregnancies with PE and it was even more effective than classical clinical 
parameters 
2- Uterine Doppler should be incorporated in the management strategy of PE 
at the clinical onset of the disease  
3- Early-onset preeclamptic patients with impaired uterine Doppler are at 
higher risk of maternal and neonatal complications. 
4- Uterine Doppler may help in the prognostic evaluation of early-PE and 
should be incorporated in the management strategy at its clinical onset 
5- Very low PlGF is a highly prevalent finding in early onset PE leading to its 
low specificity and low positive predictive value 
6- The predictive role of a low PlGF level in predicting maternal complications 
in very early PE is limited 
 
To conclude, the study of the uterus-placenta unit would seem an 
interesting parameter for the prognostic assessment of the disease. 
Future studies based in the combination of angiogenic factors and Doppler 
measurements could improve the prediction of complications in patients 
with PE. 
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